Multiple cellular and pathway-level targets – poorly resolved at molecular level

This classification refers to therapeutic targets that are defined by their systemic or cellular effects rather than by a specific, isolated molecular entity such as a single protein or receptor [1][2]. It is frequently used in the context of phenotypic drug discovery, where compounds are identified based on their ability to alter a disease-relevant phenotype in a complex biological system [4]. Because the mechanism of action involves the simultaneous modulation of multiple pathways or poorly defined molecular interactions, these targets present unique challenges for traditional structure-based drug design [1]. Drugs interacting with these targets often exhibit polypharmacology, providing therapeutic benefits through broad-spectrum activity but also carrying risks of off-target effects [3]. Examples include complex immunomodulators and certain metabolic regulators whose clinical efficacy is well-established despite an incomplete map of their molecular interactome [2][4].

Other names

Phenotypic targetsSystem-level targetsNon-specific molecular targetsPolypharmacological targetsUnresolved molecular mechanisms

Modulation of multiple biological pathways or cellular processes without a single, well-defined molecular binding site [1][4].